Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Dec;182(12):5465-5471.
doi: 10.1007/s00431-023-05213-8. Epub 2023 Sep 29.

NT-PROBNP as a screening tool for low-risk patent ductus arteriousus: a follow-up validation study

Gloria López-Blanco #  1   2 , Ignacio Oulego-Erroz #  3   4 , Álvaro Pou-Blázquez  1 , Carlos Medina-Guerrero  1 , Silvia Rodríguez-Blanco  5 , Paula Alonso-Quintela  5 , Alejandro Pérez-Muñuzuri  6 , Mari Luz Couce-Pico  6
Affiliations
Observational Study

NT-PROBNP as a screening tool for low-risk patent ductus arteriousus: a follow-up validation study

Gloria López-Blanco et al. Eur J Pediatr. 2023 Dec.

Abstract

The purpose of the study is to test whether NT-proBNP serves as a screening tool for low-risk patent ductus arteriosus and safely avoids routine early echocardiography. This is a prospective observational study in preterm infants ≤32 weeks of gestational age. Infants with ≥5100 pg/ml (positive screening) at 48-72 hours of life received comprehensive echocardiography and were treated according to shunt severity. Infants with NT-proBNP below 5100 pg/ml (negative screening) were managed expectantly. The main outcome was need for ductus treatment within the first 7 days of life. One hundred twenty-five infants were included; 82 had a negative NT-proBNP screening and 43 had a positive NT-proBNP screening. No infant (0%) with a negative screening was treated for ductus while 26 (60.4%) with a positive screening were treated (p < 0.001). NT-proBNP avoided a 65.6% of routine echocardiograms. NT-proBNP had an excellent performance to predict PDA treatment (AUC = 0.967).Conclusion: NT-proBNP at 48-72 hours of life has an excellent performance to detect low risk and avoids unnecessary echocardiograms. This may contribute to optimize PDA management in terms of resource utilization.

Keywords: Echocardiography; Natriuretic peptides; Patent ductus arteriosus; Preterm infant; Screening.

PubMed Disclaimer

References

    1. Mitra S, Scrivens A, von Kursell AM, Disher T (2020) Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants. Cochrane Database Syst Rev 12:CD013278. https://doi.org/10.1002/14651858.CD013278.pub2
    1. Mitra S, McNamara PJ (2020) Patent ductus arteriosus-time for a definitive trial. Clin Perinatol 47:617–639. https://doi.org/10.1016/j.clp.2020.05.007 - DOI - PubMed
    1. Juszczak E, Gupta S (2018) Continued uncertainty regarding treatment of patent ductus arteriosus in premature infants and the role of clinical trials. Semin Fetal Neonatal Med 23:267–272. https://doi.org/10.1016/j.siny.2018.03.004 - DOI - PubMed
    1. Hundscheid T, Jansen EJS, Onland W et al (2021) Conservative management of patent ductus arteriosus in preterm infants-a systematic review and meta-analyses assessing differences in outcome measures between randomized controlled trials and cohort studies. Front Pediatr 9:626261. https://doi.org/10.3389/fped.2021.626261
    1. Sung SI, Chang YS, Ahn SY et al (2020) Conservative non-intervention approach for hemodynamically significant patent ductus arteriosus in extremely preterm infants. Front Pediatr 8:605134. https://doi.org/10.3389/fped.2020.605134

Publication types

Substances

LinkOut - more resources